Jefferies Financial Group Reaffirms Hold Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

by · The Markets Daily

Jefferies Financial Group reissued their hold rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report released on Friday morning, Benzinga reports. Jefferies Financial Group currently has a $0.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $5.00.

Several other equities analysts also recently issued reports on MRNS. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 4th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research report on Monday, September 23rd. Eight investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $6.07.

View Our Latest Research Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Stock Up 36.9 %

MRNS opened at $0.41 on Friday. The company has a market cap of $22.31 million, a price-to-earnings ratio of -0.15 and a beta of 1.14. Marinus Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $11.26. The firm’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $1.56.

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the previous year, the business earned ($0.61) earnings per share. On average, research analysts forecast that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of MRNS. Wellington Management Group LLP increased its position in Marinus Pharmaceuticals by 54.8% during the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after purchasing an additional 85,455 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Marinus Pharmaceuticals during the first quarter worth about $664,000. Vanguard Group Inc. increased its position in shares of Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Marinus Pharmaceuticals during the first quarter valued at about $384,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Read More